Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
K. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
M. Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
S. Siena
Consultant or Advisory Role - AstraZeneca; Merck Serono; Roche
E. Van Cutsem
Research Funding - Amgen
J. Huang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. Humblet
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
J. Van Laethem
No relevant relationships to disclose
T. Andre
Honoraria - Amgen
J. S. Wiezorek
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen